Novartis yanks imatinib PAH NDA; FDA wants more data, cancels AdCom
05:13 EDT 17 Aug 2012 | SCRIP
The first sign there may be trouble with Novartis' new drug application (NDA) for imatinib as a pulmonary arterial hypertension (PAH) treatment came on 15 August when the US FDA called off the 14 September meeting of its Cardiovascular and Renal....
Original Article: Novartis yanks imatinib PAH NDA; FDA wants more data, cancels AdCom
More From BioPortfolio on "Novartis yanks imatinib PAH NDA; FDA wants more data, cancels AdCom"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
